Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters Introduces the ACQUITY QDa Detector

Published: Monday, October 07, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
The Waters® ACQUITY QDa™ Detector is the first mass detector to bring high-quality, mass spectral data to chromatographic separations.

Designed as a synergistic component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY® UltraPerformance LC® (UPLC®), ACQUITY UltraPerformance Convergence Chromatography™ (UPC2®), Alliance® high performance liquid chromatography (HPLC) and Waters supercritical fluid chromatography (SFC) and LC-based purification systems. 

“The ACQUITY QDa Detector is the realization of a vision that started 20 years ago at Waters,” said Art Caputo, President, Waters Division. "We foresaw a day when we could blend chromatography and mass spectrometry technologies together in a way that gives every analytical scientist access to mass spectral data regardless of their previous experience with mass spectrometry. The ACQUITY QDa Detector adds a whole new dimension to separation science and it is the most progressive leap forward in chromatography detection since the first photodiode detectors were introduced decades ago." 

The result of 30 years of Waters mass spectrometry experience and innovation and featuring 37 new patents and patents pending, the ACQUITY QDa Detector addresses the barriers of complexity, size and cost that have hindered the adoption of mass spectrometry for everyday use. It is purposefully designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. With the on/off simplicity that analytical scientists have long wanted from mass spectrometry, the ACQUITY QDa Detector fully automates sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. Robust and reliable enough for routine use, the ACQUITY QDa Detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a familiar photodiode array (PDA) detector.  

The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information. Additionally, the ACQUITY QDa Detector extends the limits of sample detection for a chromatographic separation by quantifying compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection.  By simplifying laboratory workflows, the detector enhances the value of every analysis and increases productivity by eliminating the need to run additional assays or turn to time-consuming alternative techniques in order to establish with certainty the levels and identity of specific sample compounds. 

The ACQUITY QDa Detector is available now for separations systems running Empower® 2 & 3 Chromatography Data System (CDS) software, including enterprise deployment with automated qualification. Empower 3 makes mass and UV spectral data processing as integrated as the separations systems they were acquired on. The ACQUITY QDa Detector is also available now for MassLynx® 4.1 Mass Spectrometry Software.

The ACQUITY QDa Detector is set to transform pharmaceutical discovery & development, chemical materials and food laboratories engaged in method development, sample profiling, synthetic chemistry and purification.

Waters is now shipping the new mass detector worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
Waters, Ireland’s NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry
Will increase large molecule characterization capacity and knowledge, help deliver new, more effective therapeutic options.
Tuesday, April 03, 2012
Waters and ACS Partner on New Sci-Mind Separation Science Training Program
From ACS Department of Professional Education, Sci-Mind learning community is designed to challenge chemists.
Friday, March 23, 2012
Waters Corporation Welcomes King’s College London into Waters Centers of Innovation Program
Aim is to support the drug control centre’s efforts to develop novel analytical methods for sports drug testing and toxicological studies.
Thursday, November 11, 2010
Waters and DAISO Sign Marketing Agreement for Bulk Process Chromatography Media
Waters to make DAISO media available to pharmaceutical and biopharmaceutical purification customers.
Thursday, February 18, 2010
Waters Acquires Thar Instruments
The acquisition establishes “Green” separation science leadership and expands chromatography application range.
Friday, February 06, 2009
Small Molecule Science Takes Center Stage at CoSMoS 2006
Researchers, journalists and academics will meet for the 3rd annual Conference on Small Molecule Science to be held from July 24-27 at the Omni Hotel, San Diego.
Tuesday, July 18, 2006
Waters Achieves top Honors Again for World-Class Customer Service
Waters Corporation receives its fifth consecutive Omega Northface Scoreboard SM Award.
Thursday, May 25, 2006
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!